This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D71 (functional disorders of polymorphonuclear neutrophils) | Special Copayment Reduction: V109 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Neutrophil dysfunction, phagocyte dysfunction, chronic granulomatous disease (chronic granulomatous disease of childhood), progressive septic granulomatosis, congenital dysphagocytosis, cell membrane receptor complex (CR3) defect, leukocyte adhesion deficiency, Functional disorders of polymorphonuclear neutrophils, Chronic granulomatous disease (CGD), Leukocyte adhesion deficiency (LAD), Congenital dysphagocytosis, Progressive septic granulomatosis |
| C. Adult onset | Likelihood of first onset in adulthood: low to moderate — most are diagnosed before age 5, but in autosomal recessive CGD with high residual oxidase activity (NCF1), female carriers of X-linked CGD, and mild LAD-I, cases first diagnosed in adulthood with pulmonary aspergillosis, nocardiosis, liver abscess, or granulomatous colitis have been reported. |
| 1. History | 1957 first description of “fatal granulomatosis of childhood” → 1967 respiratory burst and microbicidal defect identified → 1986 positional cloning of CYBB → 1980s CD18 deficiency (LAD-I) identified → interferon-γ and itraconazole prophylaxis, hematopoietic stem cell transplantation, and gene therapy. |
| 2. Causes | Congenital phagocyte defects: NADPH oxidase deficiency (CGD), β2 integrin, fucose transport, and kindlin-3 defects (LAD-I/II/III), specific granule deficiency, myeloperoxidase deficiency, Rac2 deficiency, etc.; secondary dysfunction is classified separately. |
| 3. Genetics | CGD: CYBB (X-linked, about 66%), NCF1 (about 20%), CYBA and NCF2 (about 7% each), NCF4 and CYBC1 (rare); LAD-I ITGB2, LAD-II SLC35C1, LAD-III FERMT3 — all autosomal recessive; SGD CEBPE; MPO deficiency MPO. |
| 4. General epidemiology | CGD about 1:200,000–250,000 births, male predominance (X-linked); autosomal recessive forms increase in regions with consanguinity; LAD-I less than 1 per million; MPO deficiency is common but mostly asymptomatic; median age at diagnosis 2.5–3 years. |
| 5. Pathophysiology | CGD — inability to produce superoxide → failure to kill catalase-positive bacteria and fungi, excessive inflammation and granulomas; LAD — inability to adhere to vascular endothelium and extravasate → absence of neutrophils in tissue despite marked neutrophilia, hyperactivity of the IL-23/IL-17 axis. |
| 6. Symptoms | CGD: recurrent pneumonia, suppurative lymphadenitis, liver abscess, osteomyelitis, skin abscesses, diarrhea and abdominal pain (granulomatous colitis), voiding dysfunction; LAD-I: delayed umbilical cord separation, skin and mucosal infections without pus, severe periodontitis, delayed wound healing. |
| 7. Signs | CGD: lymphadenopathy, hepatosplenomegaly, failure to thrive, pulmonary nodules and consolidation, liver abscess, gastric outlet and urinary tract obstruction; LAD-I: marked neutrophilia even without infection, absence of pus formation, gingival recession and tooth loss; anemia and elevated inflammatory markers. |
| 8. Screening | No population screening; targeted testing for deep infections with catalase-positive bacteria or fungi, recurrent abscesses, or delayed umbilical cord separation; DHR-123 flow cytometry (CGD), CD18/CD11b flow cytometry (LAD-I); family and carrier screening. |
| 9. Diagnosis | Measurement of the oxidative burst by DHR, NBT, and chemiluminescence → phagocyte oxidase protein expression → analysis of the causative gene; for LAD, testing of CD18 expression level, CD15a (sialyl-Lewis X), and integrin activation; blood smear (SGD), MPO cytochemical staining. |
| 10. Treatment | CGD: lifelong TMP-SMX and itraconazole prophylaxis ± interferon-γ, long-term targeted treatment of infections, steroids and immunomodulation for colitis; cure by hematopoietic stem cell transplantation; gene therapy research; early transplantation for severe LAD-I. |
| 11. Prognosis | CGD survival about 90% at age 10, about 46–55% at age 30; better with higher residual oxidase activity; fungal infection is the main cause of death; overall survival after transplantation about 90% or more; death in infancy is common in severe LAD-I without transplantation. |
| 12. Prevention | Genetic counseling, carrier and prenatal/preimplantation diagnosis; avoid exposure to compost, hay, gardening, and construction sites; live bacterial vaccines (BCG) contraindicated; lifelong antibacterial and antifungal prophylaxis; dental hygiene; follow-up of inflammatory diseases in female carriers. |
| 13. References | Inflammatory consequences of inherited disorders affecting neutrophil function … and 9 other papers |
ICD-10 D71 “functional disorders of polymorphonuclear neutrophils” encompasses a group of congenital phagocyte disorders in which the number of neutrophils is normal or even increased but their function is defective, causing susceptibility to infection. This category includes chronic granulomatous disease (CGD), leukocyte adhesion deficiency (LAD) corresponding to the cell membrane receptor complex (CR3) defect, congenital dysphagocytosis, and progressive septic granulomatosis, and its history largely parallels the history of CGD research.
In 1954, Janeway et al. reported boys with recurrent infections and hypergammaglobulinemia, and in 1957 Berendes, Bridges, and Good described this as a distinct disease, “fatal granulomatosus of childhood”. The affected children had recurrent suppurative lymphadenitis, hepatosplenomegaly, pulmonary infiltrates, and multiple granulomas, and most died in childhood. In 1959, Landing and Shirkey reported that pigment-laden histiocytes were characteristically observed in the tissues of these patients.
The decisive turning point came in 1967. Holmes, Page, Good, Quie, and colleagues showed that patients' neutrophils phagocytose bacteria normally but cannot kill them, and that the increase in oxygen consumption that occurs during phagocytosis, i.e., the respiratory burst, is absent. The disease was thus named “chronic granulomatous disease.” In 1968, Baehner and Nathan introduced the nitroblue tetrazolium (NBT) reduction test, establishing a simple diagnostic method.
In 1978, Segal et al. found that cytochrome b558 was absent in patients' neutrophils, and in 1986 Royer-Pokora and Orkin et al. identified CYBB (gp91phox) by positional cloning, which finds a gene from its chromosomal location alone without protein information. This is one of the first cases of a human disease gene isolated by positional cloning. Subsequently, p22phox (CYBA), p47phox (NCF1), p67phox (NCF2), p40phox (NCF4) in 2009, and EROS (CYBC1) in 2017 were identified in turn.
Leukocyte adhesion deficiency became known when Hayward et al. reported infants with delayed umbilical cord separation and recurrent infections in 1979–1980, and in the 1980s Anderson and Springer et al. identified CD11/CD18 (β2 integrin) deficiency, establishing it as LAD-I. In 1992, Etzioni reported LAD-II due to abnormal fucose metabolism, and in 2009 several research groups reported LAD-III due to kindlin-3 (FERMT3) deficiency.
On the treatment side, interferon-γ prophylaxis was established by the 1991 randomized controlled trial of the International CGD Cooperative Study Group, and itraconazole prophylaxis by the 2003 trial of Gallin et al. In 2014, Güngör et al. reported excellent results of reduced-intensity conditioning hematopoietic stem cell transplantation, and in 2020 Kohn et al. published results of lentiviral gene therapy for X-linked CGD. In Korea, studies analyzing CYBB variants in families with X-linked CGD have also been reported, and D71 is currently managed as eligible for rare disease Special Copayment Reduction.
Neutrophil dysfunctions under D71 are classified according to the stage at which there is a congenital defect in the sequence of processes in which neutrophils migrate to the site of infection and recognize, phagocytose, and kill pathogens. Neutropenia with reduced neutrophil counts (D70) and Chediak-Higashi syndrome (E70.3), among others, are classified under separate codes.
Microbicidal defect — chronic granulomatous disease (CGD)
The most representative disease of D71. One of the proteins making up the phagocyte NADPH oxidase complex is deficient, so superoxide (O₂⁻) and its downstream reactive oxygen species cannot be generated. It occurs when any one of the following is deficient: the membrane-bound components gp91phox (NOX2) and p22phox, the cytosolic components p47phox, p67phox, and p40phox, or EROS, the endoplasmic reticulum chaperone required for expression of gp91phox.
Adhesion and migration defects — leukocyte adhesion deficiency (LAD)
Granule formation defects
In specific granule deficiency (SGD), a defect in a neutrophil differentiation transcription factor prevents formation of secondary (specific) granules and granule proteins such as lactoferrin, reducing microbicidal capacity and chemotaxis.
Microbicidal enzyme defects
Myeloperoxidase (MPO) deficiency is a condition in which hydrogen peroxide cannot be converted to hypochlorous acid; it is mostly asymptomatic, but Candida infections have been reported in the presence of comorbidities such as diabetes. In severe glucose-6-phosphate dehydrogenase (G6PD) deficiency, a CGD-like phenotype rarely appears due to insufficient NADPH supply.
Signaling defects
Rac2 deficiency, β-actin defects, CARD9 deficiency, and others cause defects in neutrophil chemotaxis, phagocytosis, and fungal recognition signaling. In addition, secondary neutrophil dysfunction due to diabetes, renal failure, drugs, burns, and so on is distinguished from the congenital dysfunctions of D71 and classified under the code of the underlying disease.
Significance of clinical classification
Classification by the stage of the defect directly helps predict the pattern of infection. Microbicidal defects (CGD) are characterized by infections with catalase-positive bacteria and fungi that form abscesses and granulomas; adhesion and migration defects (LAD) by necrotizing skin and mucosal infections without pus formation and periodontitis; and granule defects (SGD) by recurrent skin and lung infections. Therefore, systematically organizing the site of infection, causative organism, and presence of pus formation is the first step in narrowing down the underlying disease.
Most diseases under D71 are monogenic diseases with well-established causative genes and inheritance patterns. In the International Union of Immunological Societies (IUIS) classification of inborn errors of immunity, they belong to the category of “congenital defects of phagocyte number or function.”
Genotypes of chronic granulomatous disease (CGD)
| Gene (protein) | Mode of inheritance | Proportion (Western) | Features |
|---|---|---|---|
| CYBB (gp91phox, Xp21.1) | X-linked recessive | About 66% | Mostly almost no oxidase activity, severe; with large deletions, contiguous gene syndrome with the McLeod phenotype and Duchenne muscular dystrophy |
| NCF1 (p47phox, 7q11.23) | Autosomal recessive | About 20% | GT deletion due to recombination with pseudogenes is common; residual activity present, so mild, diagnosis in adulthood possible |
| CYBA (p22phox, 16q24) | Autosomal recessive | About 7% | Increased frequency in regions with consanguinity |
| NCF2 (p67phox, 1q25) | Autosomal recessive | About 7% | Variable severity |
| NCF4 (p40phox), CYBC1 (EROS) | Autosomal recessive | Rare | NCF4 deficiency may be normal on DHR testing; inflammatory bowel disease-like presentation |
X-linked CGD carriers
Women heterozygous for CYBB show a mosaic pattern of normal and deficient neutrophils depending on X chromosome inactivation (lyonization). When the proportion of normal neutrophils is skewed below 20%, the risk of infection increases, and regardless of the proportion, there is a high risk of autoimmune and inflammatory conditions such as discoid lupus-like skin lesions, photosensitive rashes, stomatitis, and arthralgia. Skewing of inactivation may increase with age.
Genotypes of leukocyte adhesion deficiency
Other related genes
Specific granule deficiency is inherited in an autosomal recessive manner through variants in CEBPE or SMARCD2, and MPO deficiency through variants in MPO (17q22). Rac2 deficiency arises from dominant-negative or recessive variants in RAC2.
Implications for genetic counseling
In the X-linked form, most mothers of affected boys are carriers, and around 10% are de novo variants. Carriers within a family can be identified by DHR testing and variant analysis, and identified variants are used for prenatal diagnosis and preimplantation genetic diagnosis. In Korea as well, diverse CYBB variants were identified in 26 families with X-linked CGD, and it was reported that in Koreans, family-specific private variants are more common than particular founder variants.
All neutrophil dysfunctions under D71 are rare, and epidemiological data have accumulated mainly for CGD. The prevalence of the disease group as a whole is difficult to present as a single figure because the frequencies of individual diseases differ widely.
Chronic granulomatous disease (CGD)
In the United States and Europe, the incidence is estimated at about 1:200,000–250,000 births. In Western countries, the X-linked form accounts for about two-thirds, with a strong male predominance. In contrast, in regions with high rates of consanguinity, such as Iran, Türkiye, the Middle East, and North Africa, autosomal recessive forms account for more than half and the sex difference narrows. Registry data from Asian countries also show a majority of X-linked forms, but there are large differences in diagnostic capacity and registration rates between countries. National incidence data for Korea are limited, but many X-linked cases have been reported, mainly from specialized pediatric infection and immunology centers.
Age at diagnosis
The median age at diagnosis is about 2.5–3 years, and the majority are diagnosed before age 5. The X-linked form tends to be diagnosed earlier, and autosomal recessive forms with residual oxidase activity, such as NCF1 deficiency, later. Cases first diagnosed in adulthood, even in the 40s–60s, have also been reported; in these cases, pulmonary aspergillosis, nocardiosis, liver abscess, or Crohn disease-like colitis prompts the diagnosis.
Frequency of infections and complications
In an analysis of 268 patients with CGD followed for 40 years at the US National Institutes of Health (NIH), lung infections occurred in 87% and liver abscesses in 32% of patients. Incidence per 100 patient-years was 2.6 for Aspergillus, 1.44 for serious Staphylococcus aureus, 1.06 for Burkholderia, 0.98 for Serratia, and 0.81 for Nocardia. Inflammatory bowel complications such as colitis occur in up to about 50% of patients, and fungal infections in about 30%.
Leukocyte adhesion deficiency
The prevalence of LAD-I is estimated at less than 1 per million, and when Almarza Novoa et al. systematically compiled cases published worldwide in 2018, they numbered only in the hundreds. Frequency is higher in regions with consanguinity. LAD-II and LAD-III have been reported in only a few dozen patients worldwide.
Other
MPO deficiency is relatively common, with complete deficiency reported in about 1 in 2,000–4,000 people in Western countries, but the majority are asymptomatic and discovered incidentally on automated hematology analyzer testing. Specific granule deficiency is an ultra-rare disease with only a few dozen patients reported worldwide.
Caveats in interpreting epidemiological data
Because epidemiological data on neutrophil dysfunction are mostly based on registry data from specialized centers, mild forms and adult-onset forms may be undercounted. In particular, patients with NCF1 deficiency and female X-linked carriers may have mild infections and remain undiagnosed. In Korea as well, cases diagnosed late during evaluation of pulmonary aspergillosis or nocardiosis in adult patients have been reported, so the actual prevalence may be higher than the known figures.
Neutrophils roll along the vascular endothelium, adhere firmly (adhesion), migrate out of the vessels (transmigration), and then, following chemotaxis, reach the site of infection, phagocytose pathogens, and kill them within the phagosome. D71 diseases show defects at different stages of this cascade.
CGD: absence of oxidative killing
When normal neutrophils phagocytose a pathogen, the cytosolic components (p47phox, p67phox, p40phox) and GTP-bound Rac translocate to membrane cytochrome b558 (gp91phox–p22phox) to assemble NADPH oxidase. The activated enzyme transfers electrons from NADPH to oxygen to produce superoxide, which leads to hydrogen peroxide, hypochlorous acid via MPO, and hydroxyl radicals. In addition, potassium influx and pH changes accompanying charge movement activate granule proteases such as elastase and cathepsin G, and the oxidase is also required for formation of neutrophil extracellular traps (NETs).
In CGD, this process is absent, so patients are particularly vulnerable to catalase-positive microorganisms (Staphylococcus aureus, Burkholderia cepacia complex, Serratia marcescens, Nocardia, Aspergillus). This has been explained by the fact that in catalase-negative bacteria, the hydrogen peroxide they produce themselves remains in the phagosome and can be used for killing, whereas catalase-positive bacteria break it down. However, this hypothesis alone does not explain all susceptibility, and failure to activate granule proteases and absence of NETs are also important mechanisms.
CGD: excessive inflammation and granulomas
NADPH oxidase is required not only for microbial killing but also for the resolution of inflammation. Reactive oxygen species suppress inflammasome and NF-κB signaling and are involved in tryptophan metabolism (IDO), clearance of apoptotic neutrophils (efferocytosis), and regulation of type I interferon signaling. When the oxidase is absent, IL-1β overproduction, unresolved inflammation, and sterile granulomas form, causing inflammatory complications unrelated to infection, such as colitis, gastric outlet and urinary tract obstruction, and pulmonary granulomas.
LAD-I: inability to migrate into tissues
When CD18 is absent, neutrophils cannot adhere firmly to endothelial ligands such as ICAM-1 and cannot leave the blood vessels. As a result, neutrophils are markedly increased in the blood, but there are no neutrophils in infected tissue, causing necrotizing infections without pus formation. In addition, the absence of tissue neutrophils eliminates the neutrophil clearance signal by macrophages, so IL-23 production is not suppressed, and the IL-23/IL-17 axis becomes hyperactive, causing severe periodontitis and bone loss.
LAD-II and III, SGD, MPO deficiency
In LAD-II, the rolling step is blocked by the absence of selectin ligands, and in LAD-III, the adhesion step is blocked by the absence of integrin activation. In SGD, both chemotaxis and microbicidal activity are reduced by the absence of granule proteins and membrane receptors. In MPO deficiency, only the downstream step of oxidative killing is absent, and with compensation by other pathways it is mostly asymptomatic.
The symptoms of neutrophil dysfunction differ by the type of defect, but common features are severe bacterial and fungal infections recurring from infancy and, in some diseases, inflammatory symptoms unrelated to infection.
Symptoms of chronic granulomatous disease (CGD)
Symptoms in female carriers of X-linked CGD
Photosensitive rashes, discoid lupus-like skin lesions, recurrent oral ulcers, arthralgia, and fatigue are common, and when the proportion of normal neutrophils is low, CGD-type infections also occur.
Symptoms of leukocyte adhesion deficiency (LAD-I)
Other defects
In LAD-II, infections are relatively mild, and growth retardation, intellectual disability, and a characteristic facial appearance are present. In LAD-III, in addition to LAD-I-type infections, bleeding symptoms such as petechiae, epistaxis, and postoperative bleeding appear. Specific granule deficiency shows recurrent skin and lung infections, and MPO deficiency is mostly asymptomatic but rarely shows Candida infections.
Characteristics of symptoms in adult-onset presentation
CGD first diagnosed in adulthood is mostly a mild form with residual oxidase activity and presents as recurrent pneumonia or chronic pulmonary nodules, liver abscess of unknown cause, colitis initially diagnosed as Crohn disease that does not respond to treatment, Nocardia brain abscess, or spinal infection. Careful review of the childhood history often reveals a past history of recurrent lymphadenitis or abscesses.
Objective findings of neutrophil dysfunction can be divided into physical findings of infections and inflammatory complications, abnormal blood test results, and imaging and endoscopic findings.
Physical examination findings
Blood test findings
Imaging findings
Endoscopic and histological findings
Colonoscopy shows findings similar to Crohn disease, and histologically, non-necrotizing granulomas and pigmented macrophages are characteristic. Granulomas and microabscesses are also observed on lymph node and liver biopsies. In infected tissue in LAD-I, there is almost no neutrophil infiltration.
Caveats in interpreting test findings
In patients with CGD, fever and CRP elevation may be mild even as infection progresses, so deep infection should not be ruled out because inflammatory markers are low. In Aspergillus infection in particular, serum galactomannan and beta-D-glucan have low sensitivity, so imaging and histological examination are more important. Conversely, in LAD-I, neutrophil counts are high even without infection, so it is difficult to judge the presence of infection from changes in neutrophil count alone.
Newborn screening for neutrophil dysfunction is not currently standardized. The TREC/KREC assay used in newborn screening for severe combined immunodeficiency cannot detect phagocyte defects. Therefore, targeted testing based on clinical clues is the mainstay of screening.
Clinical situations in which testing is recommended
First-line screening tests
Family screening
DHR testing and variant analysis are performed in siblings of diagnosed patients, especially brothers and maternal male relatives in the X-linked form, and in potential carrier women such as mothers and sisters. Carrier women need to be identified to assess their own risk of inflammatory disease and for prenatal counseling.
Caveats in interpretation
DHR testing must be analyzed quickly after sample collection, and in MPO deficiency, the fluorescence signal is low and can be mistaken for CGD. In addition, in NCF4 deficiency, PMA-stimulated DHR may be normal, so particle-stimulation testing is needed. Abnormal findings must always be confirmed by confirmatory testing.
Application of screening in adult care
In adults as well, DHR testing is performed when there is invasive aspergillosis, nocardiosis, Burkholderia infection, recurrent liver abscess, or treatment-refractory granulomatous colitis without immunosuppressive factors. This test yields results within a few hours from a small amount of peripheral blood, making screening highly efficient, and if abnormal, confirmatory testing is carried out at a specialized center.
Diagnosis proceeds in the order of clinical suspicion → identification of the type of defect by functional testing → protein expression analysis → genetic analysis. The results of the initial functional tests determine the direction of subsequent testing.
Step 1: Functional testing
Step 2: Protein expression analysis
Once CGD is confirmed, expression of gp91phox, p22phox, p47phox, and p67phox is examined by flow cytometry or Western blot to infer the deficient component. Because gp91phox and p22phox are required for each other's stability, deficiency of either one reduces both.
Step 3: genetic analysis
Identification of the causative gene is essential for genetic counseling, family screening, prenatal diagnosis, and prognostic prediction. Next-generation sequencing panels test genes including CYBB, CYBA, NCF1, NCF2, NCF4, CYBC1, ITGB2, SLC35C1, FERMT3, CEBPE, MPO, RAC2. NCF1 is difficult to analyze with standard NGS because of its high homology with pseudogenes, so special methods such as analysis of the gene-to-pseudogene ratio of the GT deletion are needed. If a large CYBB deletion is suspected, involvement of adjacent genes (XK, DMD) is checked.
Assessment of infections and complications
Differential diagnosis
Crohn disease, tuberculosis and nontuberculous mycobacterial infections, sarcoidosis, hyper-IgE syndrome, severe congenital neutropenia, interferon-γ/IL-12 axis defects (Mendelian susceptibility to mycobacterial disease), CARD9 deficiency, and secondary neutrophil dysfunction (diabetes, drugs, etc.) must be differentiated.
Baseline assessment after diagnosis
Once the diagnosis is confirmed, HLA typing is used to search early for transplant donors such as siblings, and baseline assessment of chest and abdominal imaging, pulmonary function, growth parameters, liver function, and nutritional status is performed. Quantification of residual oxidase activity is used for prognostic prediction and for deciding the timing of transplantation, and testing of the carrier mother and family is also planned at this point.
Treatment consists of four pillars: prevention of infection, aggressive treatment of infection, control of inflammatory complications, and curative treatment by hematopoietic stem cell transplantation or gene therapy.
Infection prevention in CGD
Treatment of infections
The principle is to identify the causative organism by tissue examination and provide targeted treatment. Fungal infections are treated for a long period of several months or more, mainly with azoles such as voriconazole, posaconazole, and isavuconazole, and combination therapy and surgical resection are considered for refractory cases. Liver abscesses were formerly treated mainly by surgical resection, but recently a strategy of combining steroids with antibiotics to avoid surgery has been reported. In severe refractory infections, granulocyte transfusions are used as an adjunct.
Treatment of inflammatory complications
Corticosteroids are effective for granulomatous colitis and gastric outlet and urinary tract obstruction, and aminosalicylates, azathioprine, methotrexate, and others are used in combination. TNF-α inhibitors carry a high risk of fatal infection and are avoided whenever possible. Experience with agents such as vedolizumab and ustekinumab has been reported.
Curative treatment
Treatment of LAD and other defects
For severe LAD-I and LAD-III, hematopoietic stem cell transplantation is the only curative treatment and is performed as early as possible. For moderate LAD-I, prophylactic antibiotics and thorough dental care are provided, and there are reports that ustekinumab, targeting the IL-23/IL-17 axis, improved periodontitis and skin lesions. In LAD-II, oral fucose supplementation improves leukocyte function in some patients. MPO deficiency usually requires no treatment; when diabetes is present, attention is paid to glycemic control and treatment of Candida infections.
The prognosis of neutrophil dysfunction varies greatly depending on the type of disease, the degree of residual function, adherence to prophylaxis, and whether curative treatment is performed. Over the past several decades, prognosis has improved markedly with advances in prophylaxis and transplantation outcomes.
Survival in chronic granulomatous disease
CGD, in which most patients formerly died in childhood, now allows long-term survival with prophylaxis. According to the comprehensive data of GeneReviews, survival is about 90% at age 10, about 73–87% at age 20, and about 46–55% at age 30. In the NIH cohort, the median age at death increased from about 15.5 years before 1990 to about 28.1 years in the most recent 10 years. However, infection remains a major cause of death, and about 55% of deaths were due to fungal infections.
Residual oxidase activity and prognosis
In 2010, Kuhns et al. analyzed 287 patients with CGD and reported that the greater the residual superoxide production, the higher the survival rate. The group with the lowest residual activity was X-linked patients without gp91phox expression, who had the poorest prognosis, while most patients with NCF1 deficiency had residual activity and more than 80% survived beyond age 40. Quantification of residual activity is used as an important prognostic indicator for treatment decisions such as the timing of transplantation.
Complications and quality of life
Recurrent lung infections cause chronic lung damage and fibrosis, and granulomatous colitis causes growth impairment and nutritional deficiencies, affecting quality of life and long-term prognosis. Long-term steroid and immunosuppressive treatment further increases the risk of infection. Female X-linked carriers usually have no effect on life span but have a burden of autoimmune and inflammatory diseases, and when the proportion of normal neutrophils is low, there is a risk of CGD-type infections.
Prognosis after hematopoietic stem cell transplantation
Overall survival after matched donor transplantation using reduced-intensity conditioning is reported to be about 90% or more, and once donor chimerism stabilizes, infections and colitis resolve and growth recovers. Active infection before transplantation, older age, and mismatched donors are poor prognostic factors. Follow-up for the development of autoimmune disease after transplantation is needed.
Leukocyte adhesion deficiency and other defects
Most patients with severe LAD-I with CD18 expression below 2% die in infancy or early childhood without transplantation, and long-term survival is possible with early transplantation. Patients with moderate LAD-I often survive into adulthood, but tooth loss due to periodontal disease and chronic skin ulcers persist. LAD-III has a poor prognosis due to infections and bleeding and requires early transplantation. Most patients with MPO deficiency have a normal life span.
Summary of prognostic factors
Factors associated with poor prognosis include absence of residual oxidase activity (X-linked gp91phox-null type), recurrent invasive fungal infections, poor adherence to prophylaxis, severe granulomatous colitis, chronic lung damage, and delayed diagnosis. In contrast, early diagnosis, thorough prophylaxis, and early matched donor transplantation greatly improve prognosis.
Ways of preventing the occurrence of congenital neutrophil dysfunction itself are limited to genetic counseling and reproductive choices; clinical prevention focuses on prevention of infections and complications and early diagnosis.
Primary prevention: genetic counseling and reproductive choices
Secondary prevention: infection prevention
Tertiary prevention: early detection of complications
Patient and family education
Patients and families are educated about the characteristics of the disease, the importance of lifelong prophylaxis, environmental exposures to avoid, and the need for immediate medical care in case of fever or new symptoms. Patients should carry a document recording their diagnosis, medications, and major infection history so that rapid decisions can be made when visiting other medical institutions. Exposure risks in school and work environments are also discussed.
Dinauer MC. Inflammatory consequences of inherited disorders affecting neutrophil function. Blood. 2019;133(20):2130–2139. DOI: 10.1182/blood-2018-11-844563. PMID: 30898864.
Dinauer MC. Primary immune deficiencies with defects in neutrophil function. Hematology: American Society of Hematology Education Program. 2016;2016(1):43–50. DOI: 10.1182/asheducation-2016.1.43.
Leiding JW, Holland SM. Chronic granulomatous disease. In: GeneReviews®. Seattle (WA): University of Washington, Seattle; 2012 [updated 2026]. NBK99496.
Marciano BE, Spalding C, Fitzgerald A, et al. Common severe infections in chronic granulomatous disease. Clinical Infectious Diseases. 2015;60(8):1176–1183. DOI: 10.1093/cid/ciu1154. PMID: 25537876.
Kuhns DB, Alvord WG, Heller T, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. New England Journal of Medicine. 2010;363(27):2600–2610. DOI: 10.1056/NEJMoa1007097. PMID: 21190454.
The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. New England Journal of Medicine. 1991;324(8):509–516. DOI: 10.1056/NEJM199102213240801.
Gallin JI, Alling DW, Malech HL, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. New England Journal of Medicine. 2003;348(24):2416–2422. DOI: 10.1056/NEJMoa021931.
Güngör T, Teira P, Slatter M, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2014;383(9915):436–448. DOI: 10.1016/S0140-6736(13)62069-3. PMID: 24161820.
Kohn DB, Booth C, Kang EM, et al. Lentiviral gene therapy for X-linked chronic granulomatous disease. Nature Medicine. 2020;26(2):200–206. DOI: 10.1038/s41591-019-0735-5. PMID: 31988463.
Almarza Novoa E, Kasbekar S, Thrasher AJ, et al. Leukocyte adhesion deficiency-I: a comprehensive review of all published cases. Journal of Allergy and Clinical Immunology: In Practice. 2018;6(4):1418–1420.e10. DOI: 10.1016/j.jaip.2017.12.008. PMID: 29371071.